Neither outcome is guaranteed. Both depend on choices we make now, often in places that traditionally receive little ...

The European Commission has approved Sanofi’s Teizeild as the first disease-modifying therapy in the EU to delay the onset of stage 3 type 1 diabetes in adults and children with stage 2 T1D. Supported ...

There’s also an AI necklace from Nirva, which can reportedly track the wearer’s movements and moods, map social connections, ...